Growth Metrics

Nexgel (NXGL) Long-Term Deferred Tax (2021 - 2022)

Nexgel posted quarterly Long-Term Deferred Tax of $4.1 million for Q4 2022, up 23.66% year-on-year from $3.3 million in Q4 2021, and up 23.66% on a QoQ basis from $3.3 million in Q4 2021.

Nexgel (NXGL) has 2 years of Long-Term Deferred Tax data on file, last reported at $4.1 million in Q4 2022.

  • For the quarter ending Q4 2022, Long-Term Deferred Tax rose 23.66% year-over-year to $4.1 million; the trailing twelve-month figure through Dec 2022 stood at $4.1 million (up 23.66% YoY), and the FY2022 full-year result was $4.1 million, up 23.66% from the prior year.
  • Long-Term Deferred Tax for Q4 2022 stood at $4.1 million, up from $3.3 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $4.1 million in Q4 2022 and bottomed at $3.3 million in Q4 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Intuitive Surgical 156.17 Bn 151.78 Bn 1.83 Bn
2 Becton Dickinson 41.51 Bn 40.49 Bn 2.15 Bn
3 Resmed 30.43 Bn 28.77 Bn 890.98 Mn
4 West Pharmaceutical Services 22.78 Bn 22.26 Bn 296.40 Mn
5 Solventum 13.39 Bn 13.39 Bn 1.10 Bn
6 Cooper Companies 12.33 Bn 12.20 Bn 695.20 Mn
7 Align Technology 11.65 Bn 10.59 Bn 736.59 Mn
8 Baxter International 9.81 Bn 7.77 Bn 891.00 Mn
9 Aptargroup 7.39 Bn 7.19 Bn 351.91 Mn
10 Nexgel 31,199.58 -1.34 Mn 819,000.00

Historic Data

Download Data 🔒
DateValue
Dec 31, 2022 4.12 Mn
Dec 31, 2021 3.33 Mn